FULCRUM THERAPEUTICS

Fulcrum Therapeutics Announces Departure of Chief Medical Officer

11 Jul 2022 16:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

05 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2022 15:02:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

10 Jun 2022 06:02:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria

12 May 2022 16:08:53 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

09 May 2022 06:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 May 2022 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

05 May 2022 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET

02 May 2022 07:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting

01 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

17 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

03 Mar 2022 06:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

03 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET

24 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference

10 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases

10 Jan 2022 06:00:03 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jan 2022 07:00:00 By Nasdaq GlobeNewswire